Structural Analysis of the Sequence Coding for an Inducible 26-kDa Protein in Human Fibroblasts
Overview
Affiliations
When human fibroblast cells were stimulated with poly(I) X poly(C) in the presence of cycloheximide for the production of interferon-beta (IFN-beta), a 26-kDa protein could be immunoprecipitated by antiserum raised against partially purified human IFN-beta [Content, J., De Wit, L., Pierard, D., Derynck, R., De Clercq, E. & Fiers, W. (1982) Proc. Natl Acad. Sci. USA 79, 2768-2772]. In our hands this 26-kDa protein showed no antiviral activity. Other investigators have, however, reported the presence in the same conditions of a second type of IFN, a so-called beta 2 species [Weissenbach, J., Chernajovsky, Y., Zeevi, M., Shulman, L., Soreq, H., Nir, U., Wallach, D., Perricaudet, M., Tiollais, P. & Revel, M. (1980) Proc. Natl Acad. Sci. USA 77, 7152-7156] of which the mRNA structure and protein characteristics strongly suggests identity with the 26-kDa product. In this paper we describe the nucleotide sequence of the 26-kDa cDNA and part of the corresponding genomic clone. The cDNA clones were isolated from a library made with mRNA from induced human fibroblasts. As, however, the information thus obtained was still incomplete, genomic clones were isolated from a total human DNA library. In this way, the entire region coding for the 26-kDa protein was established, as well as the neighbouring sequences including the inducible promoter area. From the deduced polypeptide sequence a number of characteristics of the 26-kDa protein can be explained. It turns out that the 26-kDa protein gene and the so-called 'IFN-beta 2' gene are identical. However, extensive homology searches indicate that the 26-kDa protein does not show statistically significant sequence homology with any known interferon species. Hence, the question of whether the 26-kDa product represents a novel IFN species remains open.
Targeting IL-6 trans-signalling: past, present and future prospects.
Rose-John S, Jenkins B, Garbers C, Moll J, Scheller J Nat Rev Immunol. 2023; 23(10):666-681.
PMID: 37069261 PMC: 10108826. DOI: 10.1038/s41577-023-00856-y.
Komarova N, Panova O, Titov A, Kuznetsov A Biomedicines. 2022; 10(5).
PMID: 35625822 PMC: 9138532. DOI: 10.3390/biomedicines10051085.
IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment.
Manore S, Doheny D, Wong G, Lo H Front Oncol. 2022; 12:866014.
PMID: 35371975 PMC: 8964978. DOI: 10.3389/fonc.2022.866014.
IL-6 in inflammation, autoimmunity and cancer.
Hirano T Int Immunol. 2020; 33(3):127-148.
PMID: 33337480 PMC: 7799025. DOI: 10.1093/intimm/dxaa078.
Interleukin-6: Molecule in the Intersection of Cancer, Ageing and COVID-19.
Brabek J, Jakubek M, Vellieux F, Novotny J, Kolar M, Lacina L Int J Mol Sci. 2020; 21(21).
PMID: 33114676 PMC: 7662856. DOI: 10.3390/ijms21217937.